Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 14Gynecologic 3Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 20Breast Neoplasms 10Fallopian Tube Neoplasms 9Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Lung Neoplasms 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Hereditary Breast and Ovarian Cancer Syndrome 2Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Neoplasms, Unknown Primary 1Liver Failure 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Brenner Tumor 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 42Nivolumab 13Carboplatin 11Cyclophosphamide 10olaparib 7Paclitaxel 7Ipilimumab 7fludarabine 6Gemcitabine 6durvalumab 5lenvatinib 4cemiplimab 4atezolizumab 4Specimen Handling 4Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fulvestrant 4Fluorouracil 4Cisplatin 4Bevacizumab 4veliparib 3spartalizumab 3sacituzumab govitecan 3liposomal doxorubicin 3avelumab 3aldesleukin 3Taxes 3Interleukin-2 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × veliparib × Gynecologic × Clear all
NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 1 Completed
98 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01306032 2017-04-26

Phase II ABT-888 With Cyclophosphamide

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
124 enrolled 21 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡